Mantle Cell Lymphoma | Topics

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma
July 24, 2020

The agent is now the first and only approved CAR T-cell therapy to treat adult patients with relapsed or refractory mantle cell lymphoma.

AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19
April 15, 2020

AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection.

Phase II ZUMA-2 Study Shows Promising Safety and Efficacy Results for KTE-X19
April 06, 2020

A 1-year follow-up of the phase II ZUMA-2 study found that KTE-X19 induced durable remissions in a majority of patients with relapsed or refractory mantle-cell lymphoma.